The estimated Net Worth of Venture Fund Vii Lparch Ven... is at least 7.47 百万$ dollars as of 6 July 2016. Venture Ven owns over 400,000 units of Syros Pharmaceuticals stock worth over 7,465,791$ and over the last 10 years Venture sold SYRS stock worth over 0$.
Venture has made over 1 trades of the Syros Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Venture bought 400,000 units of SYRS stock worth 5,000,000$ on 6 July 2016.
The largest trade Venture's ever made was buying 400,000 units of Syros Pharmaceuticals stock on 6 July 2016 worth over 5,000,000$. On average, Venture trades about 66,667 units every 0 days since 2014. As of 6 July 2016 Venture still owns at least 4,637,137 units of Syros Pharmaceuticals stock.
You can see the complete history of Venture Ven stock trades at the bottom of the page.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over 8,259,551$ worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth 51,830,966$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Srinivas Akkaraju、Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of 135,148$. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth 178,365$.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: